What the Interim Compounding Pathway for Peptides Could Mean for Supplement Brands

The Department of Health and Human Services (HHS) said Oct. 28 that it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptides, provided they meet a set of conditions.¹ The policy covers BPC-157, TB-500, Epitalon, Semax, KPV, and MOTS-c, and applies while FDA develops its Section 503A bulk drug substances list through rulemaking.¹ A notice of availability is scheduled to publish in the Federal Register on Oct. 30, with comments due two weeks after publication.²

For supplement companies, the stakes are less about what pharmacies may now compound and more about what the policy signals: how these peptides may be classified as drugs or dietary ingredients, what quality documentation customers may come to expect, and how a legal prescription channel could change competition with gray-market products.

Why Does This Matter to Supplement Companies?

Dietary supplements are regulated under a different framework, with no premarket approval, so compounding policy does not directly govern supplement products. However, it still matters in four ways.

• Drug preclusion. The FD&C Act excludes from the dietary supplement definition certain articles that are approved drugs or have been authorized for investigation as drugs, a provision Nutritional Outlook has tracked through the proposed Dietary Supplement Innovation Act.³ In a July 22 letter to FDA's compounding advisory committee, the Natural Products Association (NPA) asked the agency to confirm that a 503A listing is not a drug-status determination and does not preclude peptides from other regulatory pathways, arguing that compounding and supplements fall under different statutory frameworks.⁴ NPA's central concern is that a compounding listing could be read as classifying these peptides as drugs, which would limit their future evaluation as foods or dietary ingredients.⁴ The policy applies to compounding only, so how it will bear on that analysis is unresolved.
• Quality expectations. The conditions tie compounding to lot-level testing for identity, purity, potency, and contaminants such as endotoxins, heavy metals, and microbial contamination.¹ Suppliers of peptide-based ingredients may find retailers and customers pointing to that documentation standard.
• Gray-market competition. In June, the Banned Substances Control Group (BSCG) warned that unregulated peptides and research chemicals marketed as supplements create unfair competition for GMP-compliant brands and risk category credibility.⁵ In a July 27 statement, the Council for Responsible Nutrition (CRN) said unapproved peptide drugs sold through gray-market channels are distinct from lawful dietary supplements, and that a product that functions as a drug should be regulated as one.⁶ Dustin Robinson, Esq., CPA, founding partner of LumaLex Law, said in a statement that the HHS policy "doesn’t legitimize research-use-only sellers."⁷
• What "peptide" means. NPA CEO Daniel Fabricant, PhD, told Nutritional Outlook in July that peptides are not only injectable weight-loss drugs, pointing to glutathione and food-derived peptides that developers are working on for oral use, and said the industry wants a path to market for them.⁸ A prescription-drug policy using the same word raises the odds of consumer and retailer confusion.

What Does the Interim Policy Allow?

Enforcement discretion is limited to specific forms and routes of administration. It covers BPC-157 acetate for subcutaneous, intramuscular, oral, and topical use; TB-500 acetate and MOTS-c acetate for subcutaneous or intramuscular injection; Epitalon acetate for injection in intermittent courses; KPV acetate for topical and oral use; and Semax free base for intranasal use.¹

Compounders must work from a valid patient-specific prescription and use a single active ingredient per product. They must source the bulk substance from an FDA-registered, CGMP-compliant original manufacturer with a lot-specific certificate of analysis, report serious adverse events and product quality issues to FDA's MedWatch program, and label products as compounded drugs that are not for resale.¹ Oral products require documentation of adequate bioavailability.¹ Because of the single-ingredient condition, LumaLex Law concluded that combination products, such as a BPC-157 and TB-500 blend in one vial, fall outside the policy.⁹

HHS said the approach is meant to discourage continued widespread use of research-use-only peptides from foreign manufacturers by giving patients a more controlled alternative.¹

What Does the Policy Not Do?

The document is not an FDA approval, and the six peptides are not on the 503A bulks list.¹ HHS describes the policy as interim and nonbinding, and says it may revisit it if a safety signal or product quality issue arises.² HHS's own justification notes that FDA's Center for Drug Evaluation and Research recommended against listing these peptides, while the Pharmacy Compounding Advisory Committee voted in favor.¹ BakerHostetler noted that the policy does not apply to outsourcing facilities under Section 503B or to products sold as research chemicals or dietary supplements.¹⁰

Robinson called the policy "a meaningful shift, but it is narrower than the headlines suggest." He described it as opening "a prescription-only channel through state-licensed 503A pharmacies, and that’s it," and said that because it is not binding, it "can be pulled back at any time."⁷

What Should Brands Watch?

The comment docket will show how trade groups and counsel read the policy.² HHS said FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list.² LumaLex Law noted that enforcement discretion can be withdrawn without the rulemaking required to add a peptide to the list, and that it binds only HHS, not state boards or private plaintiffs.⁹ The question of how broadly FDA reads "dietary ingredient" is also open, after industry groups urged the agency in May to broaden its interpretation.¹¹

The policy leaves the central question for supplement brands unanswered: whether compounded access strengthens, or simply coexists with, the drug-status questions peptide ingredients already face. Robinson said the businesses that come out ahead will be the ones that "vet their ingredient suppliers" and "keep their marketing claims disciplined."⁷ Until FDA or Congress addresses the drug-status question, the line between a lawful supplement peptide and an unapproved drug remains where industry counsel and the agency say it is.

References

1. US Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, including Appendices A and B. October 28, 2026. Accessed October 30, 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

2. US Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances; notice of availability. Fed Regist. Docket HHS-OASH-2026-0496. FR Doc 2026-22192. Scheduled for publication October 30, 2026. Accessed October 30, 2026. https://www.federalregister.gov/d/2026-22192

3. New bill would reform FDA drug preclusion standard for supplements. Nutritional Outlook. September 11, 2026. Accessed October 30, 2026. https://www.nutritionaloutlook.com/view/new-bill-would-reform-fda-drug-preclusion-standard-supplements

4. Natural Products Association. Comments to the FDA Pharmacy Compounding Advisory Committee on proposed additions to the 503A bulk drug substances list. July 22, 2026. Accessed October 30, 2026. https://www.npanational.org/wp-content/uploads/2026/07/FDA-advisory-committee-peptide-meeting-072226.pdf

5. BSCG warns of reputational risks from unregulated peptides and research chemicals. Nutritional Outlook. June 11, 2026. Accessed October 30, 2026. https://www.nutritionaloutlook.com/view/bscg-warns-risks-unregulated-peptides-research-chemicals

6. Council for Responsible Nutrition. Statement from the Council for Responsible Nutrition regarding peptides and recent press coverage. July 27, 2026. Accessed October 30, 2026. https://www.crnusa.org/newsroom/statement-council-responsible-nutrition-regarding-peptides-and-recent-press-coverage

7. Robinson D. Statement on HHS enforcement discretion policy for six peptides. LumaLex Law. Statement provided to Nutritional Outlook. Received October 30, 2026.

8. Inside NPA's FDA ties, mandatory registry pushback, and the fight over peptide innovation. Nutritional Outlook. July 13, 2026. Accessed October 30, 2026. https://www.nutritionaloutlook.com/view/inside-npa--fda-ties-mandatory-registry-pushback

9. Robinson D. HHS opens a temporary door for peptides. LumaLex Law. October 29, 2026. Accessed October 30, 2026. https://www.lumalexlaw.com/2026/10/29/hhs-opens-a-temporary-door-for-peptides/

10. BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. October 28, 2026. Accessed October 30, 2026. https://www.bakerlaw.com/insights/hhs-issues-enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances/

11. Industry groups urge FDA to broaden definition of dietary supplement ingredients. Nutritional Outlook. May 5, 2026. Accessed October 30, 2026. https://www.nutritionaloutlook.com/view/industry-groups-urge-fda-to-broaden-definition-of-dietary-supplement-ingredients